Merck KGaA to Relocate Its DeImmunisation Research From Scotland to U.S.

30-May-2005

Merck KGaA announced that during the course of this year it will relocate its pharmaceutical research operations in Aberdeen, Scotland, to its larger biotech research facility in the United States. The Aberdeen site focuses on research to eliminate immunogenic properties from antibodies and other therapeutic proteins.

DeImmunisation(TM) technologies aimed at developing antibodies and other protein therapeutics with superior tolerability profiles will continue to be an important asset in the discovery and development of innovative biological drugs for Merck. In the future this activity will be performed exclusively at Merck's U.S. research center, EMD Lexigen, located in Billerica, near Boston, MA. An internal evaluation revealed that synergies can be expected from a full integration of these activities with the research for New Biologic Entities taking place at EMD Lexigen. In addition, contract DeImmunisation work for external customers will no longer be offered. Eighteen employees in Scotland will be affected by the consolidation and closure of the Aberdeen site.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous